Modulation of Autophagy by Sorafenib: Effects on Treatment Response

The multikinase inhibitor sorafenib is, at present, the only drug approved for the treatment of hepatocellular carcinoma (HCC), one of the most lethal types of cancer worldwide. However, the increase in the number of sorafenib tumor resistant cells reduces efficiency. A better knowledge of the intra...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Pharmacol
Main Authors: Prieto-Domínguez, Nestor, Ordóñez, Raquel, Fernández, Anna, García-Palomo, Andres, Muntané, Jordi, González-Gallego, Javier, Mauriz, José L.
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2016
Assuntos:
Oncology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4896953/
https://ncbi.nlm.nih.gov/pubmed/27375485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00151
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares